RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line…

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)